WTI peptide vaccination for patients with high risk hematological malignancies.
Latest Information Update: 10 Nov 2021
At a glance
- Drugs INNO 305 (Primary)
- Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Therapeutic Use
- 17 Dec 2009 Actual end date (Nov 2009) added as reported by ClinicalTrials.gov.
- 17 Dec 2009 Actual end date (Nov 2009) added as reported by ClinicalTrials.gov.
- 17 Dec 2009 Actual patient number (4) added as reported by ClinicalTrials.gov.